Tenderwize
Wróć do wyszukiwania

Open house rebate agreements Abatacept, ATC L04AA24

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 03, 2028 · 614 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Abatacept, ATC L04AA24

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

30 / 100

Czynniki ryzyka

No estimated value or volume is provided. The actual business volume under the agreement is unknown and may be very low.

The agreement automatically becomes void if a nationwide or regional rebate contract for the same substance is conclude...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Non-exclusive rebate agreements for Abatacept (ATC L04AA24) as per § 130a Abs. 8 SGB V
  • Standardized contract terms, not individually negotiable
Pokaż pełne podsumowanie

Open-house model for non-exclusive rebate agreements on Abatacept (ATC L04AA24) by AOK Bayern. Any eligible pharmaceutical company can conclude a standard contract without competitive selection. Contract runs from 01 July 2026 to 30 June 2028. Rolling entry with monthly cutoffs; final deadline for contract conclusion is 03 May 2028. No estimated value or volume is provided.

Ryzyka

No estimated value or volume is provided. The actual business volume under the agreement is unknown and may be very low.

The agreement automatically becomes void if a nationwide or regional rebate contract for the same substance is conclude...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Contract and annex must be signed by an authorized representative (proof of authority required via commercial register extract or power of attorney)

Eligibility

  • Only pharmaceutical companies are eligible to participate

Administrative

  • Must submit a signed declaration of reliability

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open house rebate agreements Abatacept, ATC L04AA24

Non-exclusive rebate agreement for the active substance Abatacept. The contract is a standard, non-negotiable agreement offered to all interested pharmaceutical companies meeting eligibility criteria. The contract can be terminated with one month's notice. It automatically becomes void if a nationwide or region-specific rebate contract for the same substance is concluded via an open procedure.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Jun 2026 - Jun 2028

Kategoria

Pharmaceutical products

Termin

Deadline May 03, 2028

Szczegóły zamówienia

Data publikacji
17 May 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
336029-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30